Denali Growth Partners

Denali Growth Partners is a Boston-based specialized healthcare software investor co-leading high-growth rounds in clinical and administrative AI, including data-cleaning and clinical AI platforms such as HiLabs. The firm writes Series A, Series B, and growth-stage checks in the $5M to $25M range and positions itself as a sector specialist with healthcare software and AI as the core thesis rather than one of many verticals. The right counterparty is a CEO of a healthcare software or AI company at meaningful revenue scale, with clear differentiation in clinical or administrative use cases, strong gross retention, and a credible path to category leadership. Healthcare relevance includes RCM and claims AI, clinical decision support, data cleaning and interoperability, payer analytics, and AI applications layered onto US healthcare claims and clinical data. Founders pursuing biotech, devices, care delivery, or international-only markets should look elsewhere; Denali’s center of gravity is US healthcare software at growth stage. The right founder is a US-focused or US-aligned technical or commercial operator who has worked through Seed and Series A and is building toward category dominance with disciplined unit economics. Geographic and structural advantage is the Boston healthcare ecosystem, deep relationships with US payer and provider buyers, and connectivity into US Tier-1 growth investors and strategic acquirers. Best entry is via US healthcare software bankers, Tier-1 US Seed and Series A funds that have co-invested with Denali, or direct outreach when revenue is at the level the firm takes seriously. The team is small and selective, and diligence is rigorous, including security review, HIPAA posture, and cohort-level metrics. Lead the pitch with audited or strong revenue metrics, cohort retention, technical moat, regulatory posture under FDA where relevant, and a credible competitive positioning against US-based incumbents. Be explicit about HIPAA and SOC 2 compliance, PHI flows, and how AI quality is monitored in production. Caveats: at growth-stage check sizes, governance expectations are formal, and Denali typically engages at the board level. Ask the firm directly about reserves, follow-on behavior in down rounds, and how secondary liquidity is handled. Confirm fund vintage and remaining deployment, and reference current portfolio CEOs on operating support, US healthcare buyer introductions, and behavior in difficult quarters. Used appropriately, Denali is one of the more credible US healthcare software growth partners for category-leading AI and software CEOs; for international-focused or earlier-stage founders, it is structurally premature.